Treatment for Hepatitis

Not all hepatitis patients need to be treated. In hepatitis A and about 90% of cases of hepatitis B, the body will fight off the disease on its own. However, up to 85% of cases of hepatitis C become chronic.

If left untreated, chronic hepatitis can lead to cirrhosis, liver cancer, and even liver failure. In fact, hepatitis C is now the leading cause of liver transplants in the United States.

Fortunately, there are treatments that can help. Treatment serves to keep the virus under control and may enable patients to enjoy a longer and healthier life. Patients who receive treatment early in the course of chronic hepatitis infections have a better chance of avoiding serious liver damage.

The sooner you begin treatment after diagnosis - before the amount of virus in your blood gets too high - the better your chances are of having the treatment work.

Treatment for Hepatitis A
Treatment for Hepatitis B
Treatment for Hepatitis C

Treatment for Hepatitis A

Most hepatitis A infections are "acute." This means that the infection lasts for less than 6 months and your body is strong enough to rid your system of the virus without the help of medical treatment. Sometimes doctors prescribe medicine to treat the symptoms you may have, such as headache and nausea, and provide intravenous fluids to prevent dehydration. Most patients recover at home.

A common recommendation is to avoid alcohol, which, as a toxic substance, can weaken an already damaged liver.

A vaccine is available for the prevention of hepatitis A. It is recommended for people who come into contact with an infected person and for those traveling to a location with a high incidence of hepatitis A or unsanitary conditions that make its presence possible or likely.

Return to Top

Treatment for Hepatitis B

Fortunately, most adults can fight off a hepatitis B infection without treatment. However, in about 10% of cases, the disease develops into its chronic form. In the chronic form, hepatitis B can lead to cirrhosis, liver cancer, or liver failure.

Interferon is a protein made naturally by your body to boost your immune system and to regulate other cell functions. A manufactured form of interferon is used to treat hepatitis B. This treatment involves taking interferon by injection for about 4 months.

Not all patients respond to interferon, and sometimes re-treatment is necessary. In clinical studies, 45% of patients who are treated for hepatitis B with INTRON® A (Interferon alfa-2b, recombinant) for Injection will have no evidence of the hepatitis B virus in their blood over time.

Even if interferon treatment does not eliminate all of the hepatitis virus, in many patients it reduces the amount of hepatitis virus in the system and leads to improvement in liver function and overall health.

In addition to interferon, lamivudine was also recently approved for the treatment of hepatitis B. Lamivudine is an oral anti-viral agent that has shown benefit in clearing the virus. Ask your doctor about lamivudine for further information.

There is a vaccine available that protects against hepatitis B. Talk to your health care professional to find out if you are a candidate for hepatitis B vaccination.

See also:

Return to Top

Treatment for Hepatitis C

Hepatitis C is the most serious form of hepatitis. It develops into a chronic form in about 85% of infected patients. If left untreated, patients are placed at high risk of developing cirrhosis, liver failure, or liver cancer. Liver failure due to hepatitis C is now the leading cause of liver transplants in the United States. If you have been infected with hepatitis C for 6 months or more, your doctor may initiate medical treatment to avoid the possibility of permanent liver damage.

The current approach to treating chronic hepatitis C is combination therapy with a pegylated alpha interferon and ribavirin. One example is combination therapy with PEG-INTRON® (peginterferon alfa-2b) Powder for Injection and REBETOL® (Ribavirin, USP) Capsules. PEG-INTRON® is a modified form of alpha interferon that works by helping to boost the immune system to fight viruses. REBETOL® is an antiviral drug that is taken orally. This combination therapy was approved by the Food and Drug Administration (FDA) for the initial treatment of patients with chronic hepatitis C. Studies show that more patients with chronic hepatitis C respond to PEG-INTRON/REBETOL combination therapy than to REBETRON® Combination Therapy containing REBETOL® and INTRON® A (Interferon alfa-2b, recombinant) Injection. In clinical trials, about 52% of patients responded to PEG-INTRON/REBETOL combination therapy compared with 46% who responded with REBETRON Combination Therapy.

REBETRON Combination Therapy is a treatment option for chronic hepatitis C patients with compensated liver disease previously untreated with alpha interferon or who have relapsed following alpha interferon therapy.

PEG-INTRON® is a modified form of alpha interferon. PEG-INTRON® stays in the body for a longer time than standard interferon and therefore only has to be taken once weekly instead of three times per week as is the case with standard alpha interferons.

Both PEG-INTRON® and INTRON® A are approved for use alone or in combination with REBETOL® for the treatment of chronic hepatitis C. It is not known how both agents work in combination with REBETOL® against the hepatitis C virus.

See also:

Return to Top

Terms and ConditionsPrivacy Policy
Copyright © 2002, Schering Corporation, Kenilworth, NJ 07033. All rights reserved.
Schering Hepatitis Innovations Home Search Site Map Glossary Take Our Survey